Small-dose combined medicine composition for treating intractable hypertension
A stubborn, low-dose technology, applied in drug combinations, active ingredients of heterocyclic compounds, blood diseases, etc., can solve the problems of small toxic and side effects, antihypertensive drug side effects, etc., to achieve small side effects, significant antihypertensive effect, effective lasting effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0019] The present embodiment provides a pharmaceutical with a combination of low-dose combination therapy resistant hypertension, which comprises the following components by weight of the drug, 15mg angiotensin converting enzyme inhibitors, calcium antagonists, betablockers 8 mg, 15 mg diuretic , a receptor blockers 15 mg, nitroglycerin 0.2 mg, Ginkgo biloba 2 mg, Salvia 100 mg, estazolam 0.3 mg, diazepam 1 mg, isosorbide dinitrate 2 mg, 5 mg aspirin , aliphatic isoamyl nitrite 0.5 mg, atorvastatin calcium 4 mg, and amlodipine besylate 1mg clopidogrel hydrogen sulfate 13 mg.
[0020] Wherein said angiotensin converting enzyme inhibitor is captopril. The calcium antagonistic agent is nifedipine. The a-receptor blocker is metoprolol. The diuretic is hydrochlorothiazide.
[0021] After the above components were uniformly mixed and formed into tablets.
Embodiment 2
[0023] The present embodiment provides a pharmaceutical with a combination of low-dose combination therapy resistant hypertension, which comprises the following components by weight of the drug, 10mg angiotensin converting enzyme inhibitors, calcium antagonists, betablockers 10 mg, 10 mg diuretic , a receptor blockers 25 mg, nitroglycerin 0.1 mg, Ginkgo biloba 4mg, Salvia 80mg, estazolam 0.5 mg, diazepam 3mg, isosorbide dinitrate 1 mg, aspirin 3 mg, nitrite isoamyl fat 0.2 mg, atorvastatin calcium 8 mg, 3 mg of amlodipine besylate and clopidogrel bisulfate 8 mg.
[0024] Wherein said angiotensin converting enzyme inhibitor is captopril. The calcium antagonistic agent is nifedipine. The a-receptor blocker is atenolol. The diuretic is hydrochlorothiazide.
[0025] After the above components were uniformly mixed and formed into tablets.
Embodiment 3
[0027] The present embodiment provides a pharmaceutical with a combination of low-dose combination therapy resistant hypertension, which comprises the following components by weight of the drug, 25mg angiotensin converting enzyme inhibitor, calcium antagonist of 5 mg, 25 mg diuretic , a receptor blockers 10mg, nitroglycerin 0.3 mg, Ginkgo biloba 1 mg, Salvia 130mg, estazolam 0.1 mg, diazepam 0.5 mg, isosorbide dinitrate 3 mg, aspirin 8 mg, ethylene isoamyl nitrate lipid 0.8mg, atorvastatin calcium 2 mg, 0.5mg amlodipine besylate and clopidogrel bisulfate 20mg.
[0028] Wherein said angiotensin converting enzyme inhibitor is captopril. The calcium antagonistic agent is nifedipine. The a-receptor blocker is metoprolol. The diuretic is hydrochlorothiazide.
[0029] After the above components were uniformly mixed and formed into tablets.
[0030] The pharmaceutical compositions of the present invention can be better blood pressure, heart and stabilize cardiovascular benefit, while for...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com